Helius Medical Technologies’ (NASDAQ:HSDT; TSX:HSM) portable neuromodulation stimulator (PoNS) received FDA breakthrough designation for the treatment of gait deficit due to symptoms of multiple sclerosis (MS).
The non-implantable device is intended as a 14-week treatment to be used in conjunction with physical therapy.
“We look forward to working with FDA to process our application, with the ultimate goal of bringing our innovative technology to the aid of patients suffering with gait deficit due to MS-related symptoms, by providing them with a non-drug, non-implantable treatment that has the potential to significantly improve their ability to walk,” Philippe Deschamps, CEO of Helius, said in a statement.
PoNS Treatment is exclusively offered by authorized clinics, with multiple locations across Canada.
